open access: Quality of Clinical Trials in Gastro‐Entero‐Pancreatic Neuroendocrine Tumours

 Blogger's Note:
rare ovarian cancer endocrine/carcinoid tumors exist, therefore, a possible interest in this paper,  there may have been ovarian cancer tumors included in a study/ies,  but without looking at each individual study,  this paper does not isolate references to ovarian/ovary

         ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Table 2 describes the study populations which may or may not have included OC endocrine/carcinoid tumors

Description of the study population in the 46 identified trials.

Characteristic

No. of Studies %

Tumour location

Pancreatic neuroendocrine tumour only

Carcinoid tumours only

Both tumours

With other endocrine cancer

Table 6. Search strategy to identify published phase II and III NET treatment trials.  (Blogger's Note: search included:  carcinoid, neuroendocrine, melanoma, thyroid but no references to 'ovarian' or 'ovary' nor any specifics in the supporting references)


Quality of Clinical Trials in Gastro‐Entero‐PancreaticNeuroendocrine Tumours

"In conclusion, we found that the quality of study design and reporting in NETs treatment trials published in the last decade is poor, especially for trials testing radionuclide treatment. While poor study design and reporting has been previously described for trials in other malignancies, some unique quality issues exist for NET trials such as the inclusion of heterogenous patient populations within individual studies coupled with poor reporting of study population parameters. This has a significant impact on trial interpretability both for clinical decision‐making and future trials.
In response, we include a list of recommendations to be considered in the design of future trials in this group of tumours to ensure that future trials provide a more informative picture of the risks and benefits of systemic therapy in this patient population. We hope that our study can serve as a baseline against which improvements in clinical trial design and reporting in this patient population can be compared."